RT Journal Article
SR Electronic
T1 Smoking-dependent expression alterations in nasal epithelium reveal immune impairment linked to germline variation and lung cancer risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.24.21266740
DO 10.1101/2021.11.24.21266740
A1 de Biase, Maria Stella
A1 Massip, Florian
A1 Wei, Tzu-Ting
A1 Giorgi, Federico M.
A1 Stark, Rory
A1 Stone, Amanda
A1 Gladwell, Amy
A1 O’Reilly, MarJn
A1 Schütte, Daniel
A1 de Santiago, Ines
A1 Meyer, Kerstin B.
A1 Markowetz, Florian
A1 Ponder, Bruce A J
A1 Rintoul, Robert C
A1 Schwarz, Roland F
YR 2023
UL http://medrxiv.org/content/early/2023/03/21/2021.11.24.21266740.abstract
AB Lung cancer is the leading cause of cancer-related death in the world. In contrast to many other cancers, a direct connection to modifiable lifestyle risk in the form of tobacco smoke has long been established. More than 50% of all smoking-related lung cancers occur in former smokers, often many years after smoking cessation. Despite extensive research, the molecular processes for persistent lung cancer risk are unclear.To examine whether risk stratification in the clinic and in the general population can be improved upon by the addition of genetic data, and to explore the mechanisms of the persisting risk in former smokers, we have analysed transcriptomic data from accessible airway tissues of 487 subjects, including healthy volunteers and clinic patients of different smoking status. We developed a model to assess smoking associated gene expression changes and their reversibility after smoking is stopped, comparing healthy subjects to clinic patients with and without lung cancer. We find persistent smoking-associated immune alterations to be a hallmark of the clinic patients. Integrating previous GWAS data using a transcriptional network approach, we demonstrate that the same immune and interferon related pathways are strongly enriched for genes linked to known genetic risk factors, demonstrating a causal relationship between immune alteration and lung cancer risk. Finally, we used accessible airway transcriptomic data to derive a non-invasive lung cancer risk classifier.Our results provide initial evidence for germline-mediated personalised smoke injury response and risk in the general population, with potential implications for managing long-term lung cancer incidence and mortality.Competing Interest StatementFMar is founder, director and shareholder of Tailor Bio. All other authors declare no conflicts of interest.Funding StatementFMas was supported by a postdoctoral fellowship of the Fondation pour la Recherche Medicale (SPE201803005264). TTW was funded by the Deutsche Forschungsgemeinschaft, CompCancer Research Training Group (RTG2424), project number 377984878. Parts of this work were funded by CRUK core grant C14303/A17197 and A19274 (FMar lab). This work was funded by grants to BAJP from Cancer Research UK and by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). RCR is part funded by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014), Cancer Research UK Cambridge Centre and Royal Papworth Hospital NHS Foundation Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics approvals for sample collection from participants in this study were given by East of England Cambridge Central REC 13/EE/0012 and the National Research Ethics Service Committee South East Coast - Surrey 13/LO/0889.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon journal publication.